8-K: MariMed Reports Record Revenues but Mixed Profitability in Q4 and Full Year 2024

MariMed Inc. announces record revenues for Q4 and full year 2024, but reports a GAAP net loss despite growth in wholesale revenue and adjusted EBITDA.

Summary

• MariMed Inc. reported its financial results for the fourth quarter and the year ended December 31, 2024.
• The company achieved record revenues, with annual wholesale revenue growth of 29 percent.
• Consolidated revenue for the year was $158.0 million, compared to $148.6 million in the previous year.
• GAAP gross margin was 40 percent for the year, while non-GAAP gross margin was 43 percent.
• The company reported a GAAP net loss of $12.1 million for the year, compared to a net loss of $16.0 million in the previous year.
• Non-GAAP Adjusted EBITDA was $19.6 million for the year, with a margin of 12 percent.
• MariMed commenced growing operations in its new cultivation facility in Mt. Vernon, Illinois, in October 2024.
• Manufacturing operations in Missouri also commenced in October 2024, with wholesale distribution beginning in late December 2024.
• In March 2025, the state of Delaware approved MariMed as the owner of First State Compassion Center (FSCC).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reports record revenues and strategic expansions, the GAAP net loss and decreased EBITDA margin raise concerns. The future outlook is cautiously optimistic.

Positives

• Record revenues were achieved for Q4 and the full year 2024.
• Wholesale revenue experienced significant growth of 29 percent.
• MariMed's brands are gaining market share in key markets.
• The company successfully met its revised 2024 financial guidance.
• MariMed is expanding its operations with new facilities in Illinois and Missouri.
• The acquisition of First State Compassion Center in Delaware will contribute to future growth.

Negatives

• The company reported a GAAP net loss of $12.1 million for the year.
• Non-GAAP Adjusted EBITDA margin decreased from 17 percent to 12 percent year-over-year.
• GAAP Gross margin decreased from 44 % to 40 % year-over-year.

Risks

• The forward-looking statements are subject to risks and uncertainties, including changes in demand, legal and regulatory changes, and economic environment.
• Reductions in customer spending and the ability to recruit and retain key personnel could impact future performance.
• Disruptions from the integration efforts of acquired companies pose a risk.

Future Outlook

MariMed anticipates continued growth in 2025, driven by a full year of contribution from recent asset expansions, wholesale gains in key markets, consolidation of FSCC in Delaware, and potential accretive M&A activity.

Management Comments

• MariMed CEO Jon Levine stated that the company owns one of the strongest portfolios of cannabis brands in the industry.
• MariMed CFO Mario Pinho commented that the company maintains one of the strongest balance sheets in the cannabis industry and successfully achieved its revised 2024 financial guidance.

Industry Context

MariMed's focus on brand development and expansion in key markets aligns with the broader trend of multi-state operators seeking to establish a strong presence in the evolving cannabis industry.

Comparison to Industry Standards

• Comparing MariMed's performance to other multi-state cannabis operators like Curaleaf, Trulieve, and Green Thumb Industries, their revenue growth is competitive, but profitability metrics such as EBITDA margin lag behind some of the industry leaders.
• For example, Trulieve consistently reports higher EBITDA margins, reflecting greater operational efficiency or a different market focus.
• MariMed's focus on wholesale revenue growth is similar to strategies employed by companies like Columbia Care, which also prioritize expanding their distribution networks.
• The acquisition of FSCC in Delaware mirrors moves by other MSOs to consolidate operations and capitalize on emerging adult-use markets, similar to how Cresco Labs has expanded its footprint through strategic acquisitions.

Stakeholder Impact

• Shareholders can expect continued growth initiatives and potential long-term value creation.
• Employees may see opportunities for advancement as the company expands.
• Customers will benefit from the availability of high-quality cannabis products.
• Suppliers can anticipate increased demand as MariMed's operations grow.
• Creditors should be reassured by the company's strong balance sheet.

Next Steps

• Continue to expand wholesale operations in Illinois, Missouri, and Maryland.
• Consolidate First State Compassion Center into MariMed as Delaware prepares for adult-use sales.
• Pursue accretive M&A activity to expand market penetration.
• Leverage brands and talent to drive top-line growth and enhance profitability in 2025.

Key Dates